TSX-V:EBM • CA27783W1059
The current stock price of EBM.CA is 0.74 CAD. In the past month the price increased by 17.46%. In the past year, price decreased by -22.92%.
ChartMill assigns a technical rating of 3 / 10 to EBM.CA. When comparing the yearly performance of all stocks, EBM.CA is a bad performer in the overall market: 87.28% of all stocks are doing better.
ChartMill assigns a fundamental rating of 1 / 10 to EBM.CA. EBM.CA has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months EBM.CA reported a non-GAAP Earnings per Share(EPS) of -0.01. The EPS increased by 15.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -189.94% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|
View all stocks in the Health Care Distributors Industry | View all stocks in the Health Care Sector | View all stocks on the TSX Venture Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
Eastwood Bio-Medical Canada, Inc. is a natural health supplement distribution company. The company is headquartered in Richmond, British Columbia. The company went IPO on 2014-09-05. The firm is a licensed distributor of the Eleotin line of products, which include formulations based on natural ingredients that are presented in tea or capsule forms. The firm's Eleotin products include natural remedies for certain metabolic disorders, such as blood glucose disorders, hypertension and obesity, and can be used as a dietary supplement. Its licensed products which have Health Canada product license numbers include Eleotin A 700, Eleotin AL88, Eleotin Cal20, Eleotin V3D, Eleotin G2000, Eleotin H55, and Eleotin Zn330. Additionally, Eleotin Bentley and Eleotin LBM have received Health Canada product license numbers. Eleotin Bentley is used to promote healthy glucose levels while Eleotin LBM is recommended for hypertension relief. The company manufactures and allocates resources towards the research and development of products.
EASTWOOD BIO-MEDICAL CANADA
1130 - 4871 Shell Road
RICHMOND BRITISH COLUMBIA V6X 3Z6 CA
CEO: Yunji Kim
Employees: 1
Phone: 16042472100
Eastwood Bio-Medical Canada, Inc. is a natural health supplement distribution company. The company is headquartered in Richmond, British Columbia. The company went IPO on 2014-09-05. The firm is a licensed distributor of the Eleotin line of products, which include formulations based on natural ingredients that are presented in tea or capsule forms. The firm's Eleotin products include natural remedies for certain metabolic disorders, such as blood glucose disorders, hypertension and obesity, and can be used as a dietary supplement. Its licensed products which have Health Canada product license numbers include Eleotin A 700, Eleotin AL88, Eleotin Cal20, Eleotin V3D, Eleotin G2000, Eleotin H55, and Eleotin Zn330. Additionally, Eleotin Bentley and Eleotin LBM have received Health Canada product license numbers. Eleotin Bentley is used to promote healthy glucose levels while Eleotin LBM is recommended for hypertension relief. The company manufactures and allocates resources towards the research and development of products.
The current stock price of EBM.CA is 0.74 CAD. The price increased by 4.23% in the last trading session.
EBM.CA does not pay a dividend.
EBM.CA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
EASTWOOD BIO-MEDICAL CANADA (EBM.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.01).